comparison anticancer effects of platinum ribavirin with platinum azidothymidine via telomerase, bcl-2, mirna-21 and mirna-122 biomarkers genes expression on hepg2 cancer cell lines

Background: anticancer medication assessment is performed by numerous approaches including biomarkers gene expression. this study aimed to investigate the anticancer effects of pt-rb and pt-azton hepg2 cells. method: in this case-control study, four groups of cells were examined. group a was the control group, group b was untreated cancer cells, and groups c and d were treated with pt-azt and pt-rb, respectively. using the mtt test, lc50 was determined, and the relative gene expression of the biomarkers was assessed by rna extraction, cdna synthesis and rt-pcr. through histopathlogical study apoptotic regions of cells were compared. data analysis was done using anova and turkey’s post hoc test.results: the results showed a significant increase for the proapoptotic gene mirna-122 (19.97 ± 0 .04) in group d compared with group c (10.36 ± 0.007). also, there was a significant decrease in the antiapoptotic genes in group d, including mirna-21 (0.10 ± 0.014), telomerase (0.56 ± 0.480), and bcl-2 (0.41 ± 0.276), compared with group c (mirna-21: 2.0 ± 0.145, telomerase: 2.49 ± 0.231, and bcl-2: 2.93 ± 0.276). there were significant differences between the nearly all studied groups (p < 0.05). there were more extensive apoptotic regions in group d compared with group c.conclusion: using pt-rb has more benefits in terms of stronger anticancer effects than pt-azt on cancer cells. also, lower drug resistance and lower side effects in pt-rb were considered compared with pt-azt, indicating that it can be more effective in anti-cancer therapy.